{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:34:13Z","timestamp":1778776453313,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:00:00Z","timestamp":1415836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:00:00Z","timestamp":1415836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, produced anti-tumor effects through apoptosis induction or S-phase arrest depending on human mesothelioma cells tested. An addition of isoprenoid, geranylgeraniol but not farnesol, negated these ZOL-induced effects, indicating that the ZOL-mediated effects were attributable to depletion of geranylgeranyl pyrophosphates which were substrates for prenylation processes of small guanine-nucleotide-binding regulatory proteins (small G proteins). ZOL-treated cells decreased a ratio of membrane to cytoplasmic fractions in RhoA, Cdc42 and Rab6 but less significantly Rac1 proteins, indicating that these proteins were possible targets for ZOL-induced actions. We further analyzed which small G proteins were responsible for the three ZOL-induced effects, caspase-mediated apoptosis, S-phase arrest and morphological changes, using inhibitors for respective small G proteins and siRNA for Cdc42. ZOL-induced apoptosis is due to insufficient prenylation of Rab proteins because an inhibitor of geranlygeranyl transferase II that was specific for Rab family proteins prenylation, but not others inhibitors, activated the same apoptotic pathways that ZOL did. ZOL suppressed an endogenous topoisomerase II activity, which was associated with apoptosis and S-phase arrest in respective cells because we detected the same cell cycle changes in etoposide-treated cells. Inhibitors for geranlygeranyl transferase I and for RhoA produced morphological changes and disrupted actin fiber structures, both of which were similar to those by ZOL treatments. These data demonstrated that anti-tumor effects by ZOL were attributable to inhibited functions of respective small G proteins and topoisomerase II activity, and suggested that cellular factors were involved in the differential cell cycle changes.<\/jats:p>","DOI":"10.1038\/cddis.2014.475","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T16:42:38Z","timestamp":1415896958000},"page":"e1517-e1517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions"],"prefix":"10.1038","volume":"5","author":[{"given":"S","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,13]]},"reference":[{"key":"BFcddis2014475_CR1","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2174\/092986707781389600","volume":"14","author":"T Yuasa","year":"2007","unstructured":"Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T . Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 2007; 14: 2126\u20132135.","journal-title":"Curr Med Chem"},{"key":"BFcddis2014475_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","volume":"12","author":"JC Frith","year":"1997","unstructured":"Frith JC, M\u00f6nkk\u00f6nen J, Blackburn GM, Russell RG, Rogers MJ . Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12: 1358\u20131367.","journal-title":"J Bone Miner Res"},{"key":"BFcddis2014475_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","volume":"61","author":"PP Lehenkari","year":"2002","unstructured":"Lehenkari PP, Kellinsalmi M, N\u00e4p\u00e4nkangas JP, Ylitalo KV, M\u00f6nkk\u00f6nen J, Rogers MJ et alFurther insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol pharmacol 2002; 61: 1255\u20131262.","journal-title":"Mol pharmacol"},{"key":"BFcddis2014475_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ . Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581\u2013589.","journal-title":"J Bone Miner Res"},{"key":"BFcddis2014475_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1242\/jcs.01660","volume":"118","author":"K Wennerberg","year":"2005","unstructured":"Wennerberg K, Rossman KL, Der CJ . The Ras superfamily at a glance. J Cell Sci 2005; 118: 843\u2013846.","journal-title":"J Cell Sci"},{"key":"BFcddis2014475_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1194\/jlr.R600004-JLR200","volume":"47","author":"LP Wright","year":"2006","unstructured":"Wright LP, Philips MR . Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res 2006; 47: 883\u2013891.","journal-title":"J Lipid Res"},{"key":"BFcddis2014475_CR7","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS . Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602\u20132608.","journal-title":"Cancer Res"},{"key":"BFcddis2014475_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW . Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459\u20131468.","journal-title":"Br J Cancer"},{"key":"BFcddis2014475_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.11128","volume":"97","author":"JR Green","year":"2003","unstructured":"Green JR . Antitumor effects of bisphosphonates. Cancer 2003; 97: 840\u2013847.","journal-title":"Cancer"},{"key":"BFcddis2014475_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR . Bisphosphonates: preclinical review. Oncologist 2004; 9: 3\u201313.","journal-title":"Oncologist"},{"key":"BFcddis2014475_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","volume":"7","author":"S Okamoto","year":"2012","unstructured":"Okamoto S, Kawamura K, Li Q, Yamanaka M, Yang S, Fukamachi T et alZoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners. J Thorac Oncol 2012; 7: 873\u2013882.","journal-title":"J Thorac Oncol"},{"key":"BFcddis2014475_CR12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ijc.21977","volume":"119","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, Shipman CM . Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006; 119: 1254\u20131261.","journal-title":"Int J Cancer"},{"key":"BFcddis2014475_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1152\/physrev.00059.2009","volume":"91","author":"AH Hutagalung","year":"2011","unstructured":"Hutagalung AH, Novick PJ . Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 2011; 91: 119\u2013149.","journal-title":"Physiol Rev"},{"key":"BFcddis2014475_CR14","doi-asserted-by":"publisher","first-page":"REVIEWS3007","DOI":"10.1186\/gb-2001-2-5-reviews3007","volume":"2","author":"H Stenmark","year":"2001","unstructured":"Stenmark H, Olkkonen VM . The Rab GTPase family. Genome Biol 2001; 2: REVIEWS3007.","journal-title":"Genome Biol"},{"key":"BFcddis2014475_CR15","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1074\/jbc.M806952200","volume":"284","author":"RA Baron","year":"2009","unstructured":"Baron RA, Tavar\u00e9 R, Figueiredo AC, B\u0142azewska KM, Kashemirov BA, McKenna CE et alPhosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2009; 284: 6861\u20136868.","journal-title":"J Biol Chem"},{"key":"BFcddis2014475_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1042\/BST20120199","volume":"40","author":"C Recchi","year":"2012","unstructured":"Recchi C, Seabra MC . Novel functions for Rab GTPases in multiple aspects of tumour progression. Biochem Soc Trans 2012; 40: 1398\u20131403.","journal-title":"Biochem Soc Trans"},{"key":"BFcddis2014475_CR17","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-05-0573","volume":"65","author":"KW Cheng","year":"2005","unstructured":"Cheng KW, Lahad JP, Gray JW, Mills GB . Emerging role of RAB GTPases in cancer and human disease. Cancer Res 2005; 65: 2516\u20132519.","journal-title":"Cancer Res"},{"key":"BFcddis2014475_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","volume":"147","author":"H M\u00f6nkk\u00f6nen","year":"2006","unstructured":"M\u00f6nkk\u00f6nen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Veps\u00e4l\u00e4inen J et alA new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006; 147: 437\u2013445.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2014475_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","volume":"157","author":"J R\u00e4ikk\u00f6nen","year":"2009","unstructured":"R\u00e4ikk\u00f6nen J, Crockett JC, Rogers MJ, M\u00f6nkk\u00f6nen H, Auriola S, M\u00f6nkk\u00f6nen J . Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009; 157: 427\u2013435.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2014475_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","volume":"224","author":"MJ Rogers","year":"1996","unstructured":"Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RG, Watts DJ . Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996; 224: 863\u2013869.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2014475_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bcp.2009.10.003","volume":"79","author":"J R\u00e4ikk\u00f6nen","year":"2010","unstructured":"R\u00e4ikk\u00f6nen J, M\u00f6nkk\u00f6nen H, Auriola S, M\u00f6nkk\u00f6nen J . Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 2010; 79: 777\u2013783.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2014475_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/mutage\/18.2.105","volume":"18","author":"F Cort\u00e9s","year":"2003","unstructured":"Cort\u00e9s F, Pastor N . Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis 2003; 18: 105\u2013112.","journal-title":"Mutagenesis"},{"key":"BFcddis2014475_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrc2608","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL . DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9: 327\u2013337.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2014475_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6769-9-1","volume":"9","author":"P Ch\u00e8ne","year":"2009","unstructured":"Ch\u00e8ne P, Rudloff J, Schoepfer J, Furet P, Meier P, Qian Z et alCatalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 2009; 9: 1.","journal-title":"BMC Chem Biol"},{"key":"BFcddis2014475_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/sj.bjc.6602052","volume":"91","author":"AM Forsea","year":"2004","unstructured":"Forsea AM, M\u00fcller C, Riebeling C, Orfanos CE, Geilen CC . Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 2004; 91: 803\u2013810.","journal-title":"Br J Cancer"},{"key":"BFcddis2014475_CR26","doi-asserted-by":"publisher","first-page":"26323","DOI":"10.1074\/jbc.M402725200","volume":"279","author":"A Mammoto","year":"2004","unstructured":"Mammoto A, Huang S, Moore K, Oh P, Ingber DE . Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1\/S transition. J Biol Chem 2004; 279: 26323\u201326330.","journal-title":"J Biol Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2014475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014475","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:22:22Z","timestamp":1672960942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2014475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,13]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"alternative-id":["BFcddis2014475"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2014.475","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,13]]},"assertion":[{"value":"21 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}